These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 32610626)

  • 21. [Predictive biomarkers for tumor-relevant signaling pathways in molecular pathology].
    Bonzheim I; Fend F
    Pathologe; 2014 Feb; 35(1):93-105. PubMed ID: 24496994
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of miRNAs in the pathogenesis and therapeutic resistance of endometrial cancer: a spotlight on the convergence of signaling pathways.
    Abdelmaksoud NM; El-Mahdy HA; Ismail A; Elsakka EGE; El-Husseiny AA; Khidr EG; Ali EM; Rashed MH; El-Demerdash FE; Doghish AS
    Pathol Res Pract; 2023 Apr; 244():154411. PubMed ID: 36921547
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emerging role of N-myc downstream-regulated gene 2 (NDRG2) in cancer.
    Hu W; Fan C; Jiang P; Ma Z; Yan X; Di S; Jiang S; Li T; Cheng Y; Yang Y
    Oncotarget; 2016 Jan; 7(1):209-23. PubMed ID: 26506239
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Advances in targeting signal transduction pathways.
    McCubrey JA; Steelman LS; Chappell WH; Sun L; Davis NM; Abrams SL; Franklin RA; Cocco L; Evangelisti C; Chiarini F; Martelli AM; Libra M; Candido S; Ligresti G; Malaponte G; Mazzarino MC; Fagone P; Donia M; Nicoletti F; Polesel J; Talamini R; Bäsecke J; Mijatovic S; Maksimovic-Ivanic D; Michele M; Tafuri A; Dulińska-Litewka J; Laidler P; D'Assoro AB; Drobot L; Umezawa D; Montalto G; Cervello M; Demidenko ZN
    Oncotarget; 2012 Dec; 3(12):1505-21. PubMed ID: 23455493
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The pan-cancer mutational landscape of the PPAR pathway reveals universal patterns of dysregulated metabolism and interactions with tumor immunity and hypoxia.
    Chang WH; Lai AG
    Ann N Y Acad Sci; 2019 Jul; 1448(1):65-82. PubMed ID: 31215667
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Linking signaling pathways to transcriptional programs in breast cancer.
    Osmanbeyoglu HU; Pelossof R; Bromberg JF; Leslie CS
    Genome Res; 2014 Nov; 24(11):1869-80. PubMed ID: 25183703
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regulation of gene expression in ovarian cancer cells by luteinizing hormone receptor expression and activation.
    Cui J; Miner BM; Eldredge JB; Warrenfeltz SW; Dam P; Xu Y; Puett D
    BMC Cancer; 2011 Jun; 11():280. PubMed ID: 21711548
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multiple signaling pathways mediate interleukin-4-induced 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase type 1 gene expression in human breast cancer cells.
    Gingras S; Côté S; Simard J
    Mol Endocrinol; 2000 Feb; 14(2):229-40. PubMed ID: 10674396
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Switching Akt: from survival signaling to deadly response.
    Los M; Maddika S; Erb B; Schulze-Osthoff K
    Bioessays; 2009 May; 31(5):492-5. PubMed ID: 19319914
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression microarray meta-analysis identifies genes associated with Ras/MAPK and related pathways in progression of muscle-invasive bladder transition cell carcinoma.
    Ewald JA; Downs TM; Cetnar JP; Ricke WA
    PLoS One; 2013; 8(2):e55414. PubMed ID: 23383328
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comprehensive genomic pan-cancer classification using The Cancer Genome Atlas gene expression data.
    Li Y; Kang K; Krahn JM; Croutwater N; Lee K; Umbach DM; Li L
    BMC Genomics; 2017 Jul; 18(1):508. PubMed ID: 28673244
    [TBL] [Abstract][Full Text] [Related]  

  • 32. miR-21 as a key regulator of oncogenic processes.
    Selcuklu SD; Donoghue MT; Spillane C
    Biochem Soc Trans; 2009 Aug; 37(Pt 4):918-25. PubMed ID: 19614619
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Co-expression module analysis reveals biological processes, genomic gain, and regulatory mechanisms associated with breast cancer progression.
    Shi Z; Derow CK; Zhang B
    BMC Syst Biol; 2010 May; 4():74. PubMed ID: 20507583
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances in understanding the mechanisms of evasive and innate resistance to mTOR inhibition in cancer cells.
    Chiarini F; Evangelisti C; Lattanzi G; McCubrey JA; Martelli AM
    Biochim Biophys Acta Mol Cell Res; 2019 Aug; 1866(8):1322-1337. PubMed ID: 30928610
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gene-expression signature regulated by the KEAP1-NRF2-CUL3 axis is associated with a poor prognosis in head and neck squamous cell cancer.
    Namani A; Matiur Rahaman M; Chen M; Tang X
    BMC Cancer; 2018 Jan; 18(1):46. PubMed ID: 29306329
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Many new down- and up-regulatory signaling pathways, from known cancer progression suppressors to matrix metalloproteinases, differ widely in cells of various cancers.
    Delassus GS; Cho H; Hoang S; Eliceiri GL
    J Cell Physiol; 2010 Aug; 224(2):549-58. PubMed ID: 20432456
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic microRNAs targeting the NF-kappa B signaling circuits of cancers.
    Tong L; Yuan Y; Wu S
    Adv Drug Deliv Rev; 2015 Jan; 81():1-15. PubMed ID: 25220353
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emerging roles of angiopoietin-like 4 in human cancer.
    Tan MJ; Teo Z; Sng MK; Zhu P; Tan NS
    Mol Cancer Res; 2012 Jun; 10(6):677-88. PubMed ID: 22661548
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The m
    Uddin MB; Wang Z; Yang C
    Mol Cancer; 2021 Apr; 20(1):61. PubMed ID: 33814008
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FOXM1 in Cancer: Interactions and Vulnerabilities.
    Gartel AL
    Cancer Res; 2017 Jun; 77(12):3135-3139. PubMed ID: 28584182
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.